167 related articles for article (PubMed ID: 38563818)
1. Divergent local and systemic antitumor response in primary uveal melanomas.
Lucibello F; Lalanne AI; Le Gac AL; Soumare A; Aflaki S; Cyrta J; Dubreuil L; Mestdagh M; Salou M; Houy A; Ekwegbara C; Jamet C; Gardrat S; Le Ven A; Bernardeau K; Cassoux N; Matet A; Malaise D; Pierron G; Piperno-Neumann S; Stern MH; Rodrigues M; Lantz O
J Exp Med; 2024 Jun; 221(6):. PubMed ID: 38563818
[TBL] [Abstract][Full Text] [Related]
2. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
3. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
4. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
5. Identification of an Immunogenic Subset of Metastatic Uveal Melanoma.
Rothermel LD; Sabesan AC; Stephens DJ; Chandran SS; Paria BC; Srivastava AK; Somerville R; Wunderlich JR; Lee CC; Xi L; Pham TH; Raffeld M; Jailwala P; Kasoji M; Kammula US
Clin Cancer Res; 2016 May; 22(9):2237-49. PubMed ID: 26712692
[TBL] [Abstract][Full Text] [Related]
6. Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
Figueiredo CR; Kalirai H; Sacco JJ; Azevedo RA; Duckworth A; Slupsky JR; Coulson JM; Coupland SE
J Pathol; 2020 Apr; 250(4):420-439. PubMed ID: 31960425
[TBL] [Abstract][Full Text] [Related]
7. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients.
Valmori D; Dutoit V; Liénard D; Lejeune F; Speiser D; Rimoldi D; Cerundolo V; Dietrich PY; Cerottini JC; Romero P
J Immunol; 2000 Jul; 165(1):533-8. PubMed ID: 10861093
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.
Noyes D; Bag A; Oseni S; Semidey-Hurtado J; Cen L; Sarnaik AA; Sondak VK; Adeegbe D
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618289
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of tumor-reactive CD4
Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
[TBL] [Abstract][Full Text] [Related]
10. Analysis of inflammatory cells in uveal melanoma after prior irradiation.
Vu TH; Bronkhorst IH; Versluis M; Marinkovic M; van Duinen SG; Vrolijk J; Luyten GP; Jager MJ
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):360-9. PubMed ID: 23211827
[TBL] [Abstract][Full Text] [Related]
11. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.
Pittet MJ; Valmori D; Dunbar PR; Speiser DE; Liénard D; Lejeune F; Fleischhauer K; Cerundolo V; Cerottini JC; Romero P
J Exp Med; 1999 Sep; 190(5):705-15. PubMed ID: 10477554
[TBL] [Abstract][Full Text] [Related]
12. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.
Mougiakakos D; Johansson CC; Trocme E; All-Ericsson C; Economou MA; Larsson O; Seregard S; Kiessling R
Cancer; 2010 May; 116(9):2224-33. PubMed ID: 20209608
[TBL] [Abstract][Full Text] [Related]
14. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.
Maeurer MJ; Necker A; Salter RD; Castelli C; Höhn H; Karbach J; Freitag K; Neukirch C; Knuth A; Jäger E
Int J Cancer; 2002 Jan; 97(1):64-71. PubMed ID: 11774245
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
[TBL] [Abstract][Full Text] [Related]
16. Presence of tumor-infiltrating CD8
Johansson J; Siarov J; Kiffin R; Mölne J; Mattsson J; Naredi P; Olofsson Bagge R; Martner A; Lindnér P
Oncoimmunology; 2020 Dec; 9(1):1854519. PubMed ID: 33344043
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study.
Thomas S; Pütter C; Weber S; Bornfeld N; Lohmann DR; Zeschnigk M
Br J Cancer; 2012 Mar; 106(6):1171-6. PubMed ID: 22353812
[TBL] [Abstract][Full Text] [Related]
18. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
19. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
[TBL] [Abstract][Full Text] [Related]
20. Identification of survival-related genes and a novel gene-based prognostic signature involving the tumor microenvironment of uveal melanoma.
Lei S; Zhang Y
Int Immunopharmacol; 2021 Jul; 96():107816. PubMed ID: 34162166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
